What is Janux Therapeutics's change in accrued liabilities?

Janux Therapeutics (JANX) reported change in accrued liabilities of -$2.03M in Q1 2026.

How has Janux Therapeutics's change in accrued liabilities changed year-over-year?

Janux Therapeutics's change in accrued liabilities decreased by 217.1% year-over-year, from $1.73M to -$2.03M.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

Janux Therapeutics JANX Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

AmgenAMGN

-$959M-9.7%

XencorXNCR

-$707K+77.6%

Nektar TherapeuticsNKTR

$2.33M+91.4%

Inhibrx Biosciences, Inc.INBX

-$10.19M-453%

Nuvation BioNUVB

-$12.32M-37.8%

Summit TherapeuticsSMMT

$12.22M+658%

Other financials

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

See full

Market cap$892.81M-36.3%

Enterprise value$862.55M-36.2%

P/S65×-85.2×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's change in accrued liabilities?: Janux Therapeutics (JANX) reported change in accrued liabilities of -$2.03M in Q1 2026.
How has Janux Therapeutics's change in accrued liabilities changed year-over-year?: Janux Therapeutics's change in accrued liabilities decreased by 217.1% year-over-year, from $1.73M to -$2.03M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.